High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

Calvin Q. Pan, Myron Tong, Kris V. Kowdley, Ke Qin Hu, Ting Tsung Chang, Ching Lung Lai, Seung Kew Yoon, Samuel S. Lee, David Cohen, Hong Tang, Naoky Tsai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.

Original languageEnglish
Pages (from-to)1047-1050.e1
JournalClinical Gastroenterology and Hepatology
Volume10
Issue number9
DOIs
Publication statusPublished - 2012 Sep

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B'. Together they form a unique fingerprint.

  • Cite this